Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (747)	3/27/2008 6:26:33 PM
From: former_pgs	Respond to of 804

My feeling is that the JNK inhibitors are effectively dead. For proof, see link below to a Celgene press release suggesting that the first JNK inhibitor finished phase I... in early 2003! Note that in the current pipeline, it is still showing as having finished phase I. ir.celgene.com

To: tuck who wrote (747)	3/27/2008 11:49:51 PM
From: Miljenko Zuanic	Respond to of 804

Barr licensed CELG S.T.E.P.S. patents for some other candidate, so it is not clear to me is license valid for T??? Yes, it is long shot, but if you cut T price in half (still very healthy profit) you are seriously attacking Velcade and Revlimid economic. Miljenko

To: tuck who wrote (747)	3/28/2008 3:49:57 AM
From: idos	Respond to of 804

No generic company has yet found its way around the S.T.E.P.S. patents, but the fact that Barr has filed an ANDA suggests that they believes they can. They didn't divulged their strategy. I think that Barr likely will provide prior art to use an obvious argument and/or that their program will not infringe Celgene's. Usage of Thalomid in front-line myeloma, has been declining and longer term, it should face significant competition from Revlimid and Velcade in this setting, and a possible generic launch (I'd think in 2010). CELG indicated that its understanding of European Orphan Drug rules imply that Dacogen will need to show improved efficacy and/or show efficacy in an underserved niche. I think that Vidaza and Dacogen will be considered equivalent by physicians (unless Daco will fail in the EORTC trial, very unlikely IMO). CC-10004 (apremilast) and 11050 (another PDE4 inhibitor) are both oral TNF alpha inhibitors for psoriasis and other inflammatory indications, currently in multiple Phase II studies and I respectively. CC-4047, CC-8490 and CC-11006 in phase II and I. There are the PHRM pipeline products: oral Vidaza, currently in a dose finding Phase I, amrubicin, currently in Phase III and the HDAC program (MGCD0103), currently in Phase Ib trials. Also CELG should have enough cash for additional acquisitions.